* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Cell Genesys

BUYINS.NET: ETH, NCC, ADEP, CBMX, CEGE, DRYS Have Been Added To Naked Short List Today

tmcnet.com
May 1, 2008 23 related
        

BUYINS.NET: ETH, NCC, ADEP, CBMX, CEGE, DRYS Have Been Added To Naked Short List Today ... BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Ethan Allen Interiors Inc. (NYSE:...

add comment
                   
tmcnet.com: Welcome to TMCnet.com tmcnet.com

Japan Pharmas' Love for U.S. Biotechs Just Heating Up

tmcnet.com
Apr 25, 2008
        

Japan Pharmas' Love for U.S. Biotechs Just Heating Up ... Can biotech save the Japanese pharmaceutical industry? Certainly there's been an interesting love affair taking place lately between Japan's largest pharmaceutical company and the U.S. biotech sector. If you think...

add comment

Streetinvesting.com: Progressive Following on Cell Genesys, Inc.

tmcnet.com
Apr 24, 2008 20 related
        

Streetinvesting.com: Progressive Following on Cell Genesys, Inc. ... Streetinvesting.com has now resumed our progressive Cell Genesys, Inc. (NASDAQ:CEGE) as it opened up $0.03 on below average volume early trading Thursday, April 24, 2008. Cell Genesys, Inc. announced...

add comment

Cell Genesys to Webcast First Quarter 2008 Conference Call

euroinvestor.co.uk
Apr 24, 2008
        

Cell Genesys, Inc. (Nasdaq:CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial of.. - Read more ... Cell Genesys, Inc. (Nasdaq:CEGE) today announced that Stephen A....

add comment

SAN DIEGO--- Ceregene Announces Two Key Additions to Leadership Team

freshnews.com
Apr 23, 2008 2 related
        

Ceregene, Inc., a biopharmaceutical company, today announced that it has added two key people to its management team. Maurice Mezzino has been hired to the position of vice president, chief business officer, and Andrea Loewen-Rodriguez joins the company as senior director, regulatory affairs....

add comment

Pfeffer Named CFO Of MannKind

tmcnet.com
Apr 17, 2008 3 related
        

Pfeffer Named CFO Of MannKind ... April 17, 2008 (FinancialWire) Matthew J. Pfeffer will join MannKind Corp. (NASDAQ: MNKD) (Current Market Cap: US$ 222.11 Mil.) as corporate vice president and chief financial officer, effective April 21. Pfeffer previously served as CFO...

add comment

Cell Genesys details cancer treatment trial

ibtimes.com
Apr 15, 2008 11 related
        

Cell Genesys Inc. said Tuesday that GVAX immunotherapy for prostate cancer, when used with ipilimumab, induces a cellular immune response that may be associated with a drop in prostate-specific antigen serum levels. ... The South San Francisco, Calif.-based drug...

add comment

Cell Genesys Reports Positive Preclinical Data - Stock at 3.20 in Early After-Hours

tmcnet.com
Apr 14, 2008
        

Cell Genesys Reports Positive Preclinical Data - Stock at 3.20 in Early After-Hours ... Boston, Apr 14, 2008 (MidnightTrader via COMTEX News Network) -- Cell Genesys (CEGE) announced data from a preclinical study demonstrating that multiantigen immunotherapies provide...

add comment

Cell Genesys says cancer treatment does well in early trial (at bizjournals.com)

yahoo.com
Apr 11, 2008 7 related
        

Inc. said Friday its GVAX treatment did well in an early stage clinical test in men with recurrent prostate cancer. The South San Francisco company (NASDAQ: CEGE) is presenting data from this Phase I/II clinical trial at a cancer conference in San Diego today. This trial...

add comment
                   

InPlay: Cell Genesys announces 'encouraging' results from Phase 1/2 trial of GVAX immunotherapy...

yahoo.com
Apr 11, 2008 10 related
        

9:30AM Textron expects Q1 EPS to exceed prior guidance 57.40 unch : Co issues upside guidance for Q1 (Mar), sees EPS of to exceed $0.75-0.85 vs. $0.83 First Call consensus. Nasdaq futures vs fair value: -24.8. : 9:00AM Lan Airlines S.A. says system passenger traffic for...

add comment